Mitochondrial Diseases Conference 2021
October 15-16, 2021
Mitocon and its scientific committee are pleased to announce the Mitochondrial Disease Conference 2021. Because of the ongoing situation with Covid-19, it will be organized again as a virtual event.
The meeting will bring together physicians, researchers, stakeholders, and patients and it will be a unique opportunity to discuss and update on current understandings of mitochondrial diseases and pathways towards diagnosis and treatment.
Mitochondrial diseases are very complex disorders, still little known by the scientific community, with multi-system manifestations and different ages of onset, ranging from infancy to adulthood. In recent years, giant steps have been taken in the study of the basic mechanisms involved in these diseases and we have finally moved from the diagnosis to the study of possible treatments.
Since its first edition in 2011, the annual Italian Meeting on Mitochondrial Diseases has contributed to this process by gathering the entire community of Italian doctors and researchers around the association of patients and helping to strengthen international partnerships and collaborations, making the whole community grow together and contributing to sharing knowledge and research progress. Since previous edition, the Mitocon conference is entirely in English to facilitate participation of doctors and researchers from all over the world, promoting international exchange and collaboration, crucial to fight together against mitochondrial diseases.
The program, drawn up in collaboration with Mitocon’s Scientific Committee, has been designed to inspire the integration of technology and innovation into medical practice. In addition, we will discuss about the natural history of some devastating mitochondrial diseases, and about new exciting models to treat these diseases.
A very important session will be dedicated to the research of therapies, with a specific focus on an update on current clinical trials and a round table with the most active industries in the field. It will be a unique opportunity for discussion between clinicians and industry and a real possibility for new collaborations. Finally, a round table with the different International Patients Advocacy Organizations will be organized, where the patients voice and their needs will be discussed with the medical community.
Loocking forward to seeing you virtually soon!
Mitochondrial Diseases Conference 2021 will be an opportunity to discuss and update on current understandings of mitochondrial diseases and pathways towards diagnosis and treatment.
PRELIMINARY PROGRAMME (confirmed speakers)
Friday, October 15th
9.00 am – 9:30 am (CEST time) Opening
9.30 am – 11.30 am Session 1: new insight on the mitochondrial domains
- Alessandro Prigione, University Children’s Hospital, Heinrich-Heine-University, Düsseldorf, Germany
- Valerio Carelli, IRCCS Institute of Sciences, Neurological (ISBN), Bellaria Hospital, Bologna/University of Bologna, Italy
- Thomas Klopstock, Ludwig-Maximilians-University of Munich, Germany
11:40 am – 12:10 pm Break
12.15 pm – 1:00 pm Keynote lecture
- Leonid Sazanov, Institute of Science and Technology, Austria
1.00 pm – 2.00 pm Lunch break
2.00 pm – 4.00 pm Session 2: translation from the lab to the clinical practice
- Carlo Viscomi, University of Padova, Italy
- Alberto Burlina, U.O.C. Malattie Metaboliche Ereditarie, A.O.U University of Padova, Italy
- Carlos Moraes, University of Miami, Miller School of Medicine, USA
4.00 pm – 4.30 pm Break
4.30 pm – 6.30 pm Session 3: exploring phenotypes
- Giovanni Manfredi, Weill Cornell Medical College, USA
- Laurance A. Bindoff Helse, Haukeland University Hospital, Bergen, Norway
- Grainne Gorman, The Wellcome Trust Centre for Mitochondrial Research, Newcastle University, UK
- Shamima Rahman, UCL GOS Institute of Child Health, UK
6.30 pm End of day 1
Saturday October 16th
9.00 am – 11:30 am Session 4: challenges and pitfalls in clinical trials design
- Jan Smeitink, Chief Executive Officer, Khondrion BV
- Gene Kelly, Executive Director, Stealth BioTherapeutics
- Magnus Hansson, Chief Medical Officer/VP:Clinical Dvlpmt, Abliva AB
- Alejandro Dorenbaum, Chief Medical Officer, Reneo Pharmaceuticals
- Salvatore Funiciello, Medical Director, Zogenix, Inc.
- John C. Campbell, Head, US Clinical Development, Minovia Therapeutics
- Xavier Llòria, Global Program Leader Raxone, Santhera Pharmaceuticals Holding AG
- Magali Taiel, Chief Medical Officer, Gensight-Biologics
- Matthew Klein, Chief Development Officer, PTC Therapeutics
11.30 am – 12.00 pm Break
12.00 pm – 1.30 pm Session 5: patients voice and their needs
Piero Santantonio, Past President, Mitocon – Insieme per lo Studio e la Cura delle Malattie Mitocondriali ODV
- Kira Mann, Chief Executive Officer, MitoAction and Chair, International Mito Patients (IMP)
- Philip Yeske, Science & Alliance Officer, United Mitochondrial Disease Foundation (UMDF)
- Sean Murray, Chief Executive Officer, Mito Foundation
- Kate Murray, Chief Executive Officer and President, MitoCanada
- Emma Del-Rey, President, A.M.Mi
1.30 pm – 2.00 pm Closing the conference
Scientific programme committee
Enrico Bertini, Neuromuscular and Neurodegenerative Disorders, Bambino Gesù Children’s Research Hospital, Rome
Valerio Carelli, IRCCS Institute of Neurological Sciences (ISBN), Bellaria Hospital, Bologna/University of Bologna
Massimiliano Filosto, NeMO Clinical Center-Brescia for Neuromuscolar Diseases; Department of Clinical and Experimental Sciences, University of Brescia
Costanza Lamperti, Division of Medical Genetics and Neurogenetics, Mariani Foundation Center for the Study of Mitochondrial Pediatric Diseases, Foundation IRCCS Neurological Institute “C. Besta”, Milan
Michelangelo Mancuso, AOUP, Neurological Institute, University of Pisa
Olimpia Musumeci, AOU Policlinico “G.Martino”, University of Messina
Serenella Servidei, Neurology Institute, Catholic University of the Sacred Heart, Rome
Valeria Tiranti, Division of Medical Genetics and Neurogenetics, Mariani Foundation Center for the Study of Mitochondrial Pediatric Diseases, Foundation IRCCS Neurological Institute “C. Besta”, Milan
Speakers to be announced.
Mitocon is an association of patients affected by mitochondrial diseases and their families striving to advance research towards a cure.
Encouraging collaboration and the exchange of knowledge within the scientific community is our priority. We would be grateful if you could support our commitment and work with a donation.